A statement about Biogen Political Action Committee

January 13, 2021 • Company Statements
Following last week’s deeply concerning events in Washington DC, we are suspending all political donations to allow a thorough review of our political contribution criteria and policies. Biogen supports the rule of law and democratic process and calls for a peaceful transition of power.
thumb
September 21, 2021
Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience

33 early and late-stage clinical programs across modalities and innovative discovery platforms Uniquely positioned to lead in Alzheimer’s disease with ADUHELM ® (aducanumab-avwa) and industry-leading pipeline including Phase 3 lecanemab Potential to transform standard of care in several areas of

Read More
thumb
September 20, 2021
FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)

BYOOVIZ™ becomes the first ophthalmology biosimilar to gain FDA approval in the United States INCHEON, Korea and CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S.

Read More